Overcoming the three biases obscuring the science of renal denervation in humans: Big-day bias, check-once-more bias and I-will-take-it-now bias

Trends in Cardiovascular Medicine

Volumn 25, Issue 2, 2015, Pages 116-118

  Howard, James P ^a   Francis, Darrel P ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

APNEA HYPOPNEA INDEX; BIOLOGICAL ACTIVITY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIAC RESYNCHRONIZATION THERAPY; EDITORIAL; EFFECT SIZE; HUMAN; KIDNEY DENERVATION; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; STUDY DESIGN; SYMPATHETIC NERVE; SYMPATHETIC TONE; HYPERTENSION, RENAL; INNERVATION; KIDNEY; PROCEDURES; SYMPATHECTOMY;

HUMANS; HYPERTENSION, RENAL; KIDNEY; SYMPATHECTOMY;

EID: 84923034579     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.10.011     Document Type: Editorial

References (15)

1. Esler M. Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med 2014, this issue.
2. Bhatt D.L., Kandzari D.E., O'Neill W.W., D'Agostino R., Flack J.M., Katzen B.T., et al. A controlled trial of renal denervation for resistant hypertension. New Engl J Med 2014, 370:1393-1401.
3. Evelyn K.A., Singh M.M., Chapman W.P., Perera G.A., Thaler H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med 1960, 28:188-221.
4. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
5. Symplicity HTNI., Esler MD, Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
6. Witkowski A., Prejbisz A., Florczak E., Kadziela J., Śliwiński P., Bieleń P., et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58:559-565.
7. Mahfoud F., Schlaich M., Kindermann I., Ukena C., Cremers B., Brandt M.C., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
8. Schlaich M.P., Straznicky N., Grima M., Ika-Sari C., Dawood T., Mahfoud F., et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. J Hypertens 2011, 29:991-996.
9. Aarab G., Lobbezoo F., Hamburger H.L., Naeije M. Variability in the apnea-hypopnea index and its consequences for diagnosis and therapy evaluation. Respiration 2009, 77:32-37.
10. Howard J.P., Cole G.D., Sievert H., Bhatt D.L., Papademetriou V., Kandzari D.E., et al. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol 2014, 172:29-35.
11. Shun-Shin M.J., Howard J.P., Francis D.P. Removing the hype from hypertension. Br Med J 2014, 348:g1937.
12. Howard J.P., Nowbar A.N., Francis D.P. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 2013, 99:1579-1587.
13. Symplicity flex: no benefit of renal denervation in mild resistant hypertension. ; 2014. http://www.tctmd.com/show.aspx?id=126865.
14. Sohaib S.M., Chen Z., Whinnett Z.I., Bouri S., Dickstein K., Linde C., et al. Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. Eur J Heart Fail 2013, 15:1419-1428.
15. Sohaib S.M., Whinnett Z.I., Ellenbogen K.A., Stellbrink C., Quinn T.A., Bogaard M.D., et al. Cardiac resynchronisation therapy optimisation strategies: systematic classification, detailed analysis, minimum standards and a roadmap for development and testing. Int J Cardiol 2013, 170:118-131. International Working Group on Quantitative O.